ES2000269A6 - Procedimiento para preparar formas medicamentosas solidas, que contienen 9-desoxo-11-desoxi-9,11-(iminon2-(2-metoxietoxi)-etiliden)-oxi-(9s)-eritromicina como substancia activa - Google Patents

Procedimiento para preparar formas medicamentosas solidas, que contienen 9-desoxo-11-desoxi-9,11-(iminon2-(2-metoxietoxi)-etiliden)-oxi-(9s)-eritromicina como substancia activa

Info

Publication number
ES2000269A6
ES2000269A6 ES8600197A ES8600197A ES2000269A6 ES 2000269 A6 ES2000269 A6 ES 2000269A6 ES 8600197 A ES8600197 A ES 8600197A ES 8600197 A ES8600197 A ES 8600197A ES 2000269 A6 ES2000269 A6 ES 2000269A6
Authority
ES
Spain
Prior art keywords
active substance
erythromycin
metoxietoxi
iminon2
etiliden
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8600197A
Other languages
English (en)
Inventor
Alain Etienne
Peter Gruber
Ulrich Busch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of ES2000269A6 publication Critical patent/ES2000269A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBE UN PROCEDIMIENTO PARA PREPARAR FORMAS MEDICAMENTOSAS SOLIDAS PARA LA ADMINISTRACION POR VIA ORAL, QUE PROPORCIONAN VALORES DE NIVELES EN SANGRE Y EN TEJIDO, ALTOS Y LARGAMENTE PERSISTENTES, QUE CONTIENEN 9-DESOXO-11-DESOXI-9,11-IMINO-2-(2-METOXIETOXI)-ETILIDEN-OXI-(9S)-ERITROMICINA COMO SUSTANCIA ACTIVA, PRESENTANDOSE LA SUSTANCIA ACTIVA INTIMAMENTE MEZCLADA CON UNA SUSTANCIA AUXILIAR BASICA EN UNA RELACION DE 1 MOL DE SUSTANCIA ACTIVA A POR LO MENOS DOS EQUIVALENTES-GRAMO DE SUSTANCIA AUXILIAR BASICA, Y QUE ESTAN REVESTIDAS CON UN BARNIZ RESISTENTE A LOS JUGOS GASTRICOS, QUE ES SOLUBLE EN UN MARGEN DE PH ENTRE 5,5 Y 6,8. LAS FORMAS MEDICAMENTOSAS SOLIDAS ABARCAN TABLETAS, GRANULOS O GRANULADOS; A PARTIR DE ESTOS ULTIMOS SE PUEDE PRODUCIR TAMBIEN UN JARABE.
ES8600197A 1985-07-10 1986-07-09 Procedimiento para preparar formas medicamentosas solidas, que contienen 9-desoxo-11-desoxi-9,11-(iminon2-(2-metoxietoxi)-etiliden)-oxi-(9s)-eritromicina como substancia activa Expired ES2000269A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853524572 DE3524572A1 (de) 1985-07-10 1985-07-10 Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
ES2000269A6 true ES2000269A6 (es) 1988-02-01

Family

ID=6275375

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600197A Expired ES2000269A6 (es) 1985-07-10 1986-07-09 Procedimiento para preparar formas medicamentosas solidas, que contienen 9-desoxo-11-desoxi-9,11-(iminon2-(2-metoxietoxi)-etiliden)-oxi-(9s)-eritromicina como substancia activa

Country Status (25)

Country Link
US (1) US4755385A (es)
EP (1) EP0208971B1 (es)
JP (1) JPH0688905B2 (es)
KR (1) KR930010586B1 (es)
AT (1) ATE63819T1 (es)
AU (1) AU586262B2 (es)
CA (1) CA1271138A (es)
DD (1) DD248057A5 (es)
DE (2) DE3524572A1 (es)
DK (1) DK165670C (es)
ES (1) ES2000269A6 (es)
FI (1) FI85649C (es)
GR (1) GR861762B (es)
HK (1) HK79791A (es)
HU (1) HU195730B (es)
IE (1) IE58951B1 (es)
IL (1) IL79375A (es)
MX (1) MX9202785A (es)
NL (1) NL970004I2 (es)
NO (1) NO175351C (es)
NZ (1) NZ216794A (es)
PH (1) PH26147A (es)
PT (1) PT82949B (es)
SG (1) SG72191G (es)
ZA (1) ZA865105B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
MX9603480A (es) * 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
US6495180B1 (en) 1995-12-22 2002-12-17 Tamer International, Ltd. Acid reduced whole bean coffee and process
US6066342A (en) * 1995-12-22 2000-05-23 Tamer International, Ltd. Antacid composition
US5853787A (en) * 1995-12-22 1998-12-29 Tamer International Method for reducing coffee acidity
US6045843A (en) * 1995-12-22 2000-04-04 Tamer International, Inc. Acid-reduced, whole bean coffee process
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6096328A (en) 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US20020018754A1 (en) * 1999-03-15 2002-02-14 Paul Albert Sagel Shapes for tooth whitening strips
ES2246238T3 (es) 1999-06-07 2006-02-16 Altana Pharma Ag Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido.
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
ATE285220T1 (de) 1999-07-02 2005-01-15 Procter & Gamble Zusammenstzungen enthaltend organosiloxan-harze zur freisetzung von mundpflegewirkstoffen und zur verlängerung der freisetzung
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2002000182A2 (en) * 2000-06-28 2002-01-03 The Procter & Gamble Company Structures and compositions increasing the stability of peroxide actives
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US6949240B2 (en) * 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
PT2559430E (pt) 2005-03-22 2015-10-09 Stada Arzneimittel Ag Ibuprofeno solubilizado
CA2617051C (en) * 2005-07-29 2013-12-17 Stichting Groningen Centre For Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
JPWO2007126039A1 (ja) * 2006-04-28 2009-09-10 塩野義製薬株式会社 マクロライド系抗生物質の被覆製剤
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN104736133B (zh) 2012-10-17 2020-07-10 宝洁公司 用于递送口腔护理活性物质的条带以及施用口腔护理活性物质的方法
GB2533593A (en) * 2014-12-22 2016-06-29 Parkside Flexibles (Europe) Ltd Package

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
AT342770B (de) * 1975-04-07 1978-04-25 Thomae Gmbh Dr K Verfahren zur herstellung neuer erythromycinderivate
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法

Also Published As

Publication number Publication date
PT82949A (de) 1986-08-01
ZA865105B (en) 1988-03-30
PH26147A (en) 1992-03-18
ATE63819T1 (de) 1991-06-15
EP0208971A3 (en) 1988-01-27
NL970004I2 (nl) 1997-06-02
FI862898A7 (fi) 1987-01-11
IE861842L (en) 1987-01-10
AU5987686A (en) 1987-01-15
NO862772D0 (no) 1986-07-09
FI85649B (fi) 1992-02-14
IL79375A (en) 1990-01-18
IL79375A0 (en) 1986-10-31
EP0208971B1 (de) 1991-05-29
JPS6212717A (ja) 1987-01-21
KR930010586B1 (ko) 1993-10-30
IE58951B1 (en) 1993-12-01
AU586262B2 (en) 1989-07-06
PT82949B (pt) 1989-01-30
DD248057A5 (de) 1987-07-29
HU195730B (en) 1988-07-28
NL970004I1 (nl) 1997-04-01
DK165670C (da) 1993-06-07
NO175351B (no) 1994-06-27
HK79791A (en) 1991-10-18
FI862898A0 (fi) 1986-07-10
DK324786D0 (da) 1986-07-08
NO175351C (no) 1994-10-05
NZ216794A (en) 1988-11-29
DK165670B (da) 1993-01-04
DK324786A (da) 1987-01-11
EP0208971A2 (de) 1987-01-21
NO862772L (no) 1987-01-12
CA1271138A (en) 1990-07-03
JPH0688905B2 (ja) 1994-11-09
FI85649C (fi) 1992-05-25
HUT42945A (en) 1987-09-28
GR861762B (en) 1986-11-10
DE3679463D1 (de) 1991-07-04
US4755385A (en) 1988-07-05
DE3524572A1 (de) 1987-01-15
MX9202785A (es) 1992-06-30
SG72191G (en) 1991-11-22
KR870000920A (ko) 1987-03-10

Similar Documents

Publication Publication Date Title
ES2000269A6 (es) Procedimiento para preparar formas medicamentosas solidas, que contienen 9-desoxo-11-desoxi-9,11-(iminon2-(2-metoxietoxi)-etiliden)-oxi-(9s)-eritromicina como substancia activa
HUT58511A (en) Process for producing pharmaceutical compositions comprising toremifen and its metabolites, suitable for ceasing the simultaneous resistance of cancer cells to several cytotoxic active ingredients
GB1468172A (en) Oral drug preparations
NO863796D0 (no) Fremgangsmaate for fremstilling av farmakologiske preparater med forlenget virkningstiden.
HU892559D0 (en) Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient
DE3686936D1 (de) Am zielorgan wirkendes enterales abgabesystem.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
NZ225242A (en) Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs
CS8804389A2 (en) Method of pharmaceutical preparation formulation with laminar structure for transdermal administration of active substance with null kinetic order
ES2055775T3 (es) Nueva forma de dosificacion.
PL317996A1 (en) Carbamazepinic form of a drug with retarded release of biologically active substance
ES8702140A1 (es) Un procedimiento para la preparacion de una composicion de etoposido en forma de dosis unitaria para administracion oral
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
IE44419B1 (en) Analgesic composition
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
GB1375806A (es)
Lucas et al. Sustained Action Tetracycline Preparation–Tetrabid-Organon Blood Level Study
ES8303915A1 (es) "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina".
ES2004693A6 (es) Un procedimiento para la preparacion de una composicion farmaceutica solida administrable por via oral, que contiene vinburnina como principio activo.
GR3002665T3 (en) Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host
JPS6442436A (en) Rheumatoid arthritis therapeutical composition

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20060710